분자세포 유전학 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 기술별, 제품별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Molecular Cytogenetics Market Size, Share & Trends Analysis Report By Application, By Technology, By Product, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,413,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,827,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,655,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

분자세포 유전학 시장 개요

세계 분자세포 유전학 시장 규모는 2024년 24억 달러로 추정되며, 2025-2033년 11.7%의 연평균 복합 성장률(CAGR)로 성장하여 2033년에는 63억 9,000만 달러에 달할 것으로 예측됩니다. 임상 진단 및 연구, 특히 종양학, 유전성 질환, 산전 검사에서 분자세포유전학 기법의 활용이 증가하고 있는 것이 시장 확대를 뒷받침하고 있습니다.

이러한 도구는 염색체 이상에 대한 고해상도 분석을 제공하며, 최신 검사실 및 임상 워크플로우에 필수적입니다. 형광 in situ hybridization(FISH), 비교 유전체 하이브리드화(CGH), 어레이 기반 기법의 적용이 확대되고 있는 것도 분자세포유전학의 채택 확대에 기여하고 있습니다. 개인 맞춤형 의료에 대한 사용 확대, 자동화 및 영상화 기술 향상으로 병원, 학술 기관, 연구센터 시장 수요가 지속적으로 증가하고 있습니다.

유전체 데이터의 양이 증가함에 따라 멀티오믹스 접근법의 통합과 생물정보학 도구의 발전으로 분자세포유전학 분야가 크게 강화되고 있습니다. 이러한 기능 강화는 대규모 유전체 데이터 세트의 관리, 분석 및 해석을 용이하게 하고, 염색체 변화와 질병과의 유의미한 연관성을 쉽게 발견할 수 있도록 돕습니다. 그 결과, 분자세포 유전학에 대한 수요가 확대될 것으로 예상되며, 연구실은 연구와 진단 모두에서 이러한 도구에 대한 의존도를 높이고 있습니다.

2023년 12월, 루핀다이애그노스틱스는 타밀나두 주 첸나이에 최신식 지역 레퍼런스 연구소를 개설했습니다. 이 연구소에서는 유세포분석, 세포진단 등과 함께 분자진단학, 특히 세포유전학 등 다양한 서비스를 제공합니다. 이번 확장으로 고품질 분자세포유전학 검사에 대한 지역 내 접근성이 강화되고, 인도 남부 지역의 진단 능력 향상에 도움이 될 것으로 기대됩니다. 이러한 주요 진단업체들의 투자는 일상적인 임상에서 세포유전학의 중요성을 입증하고, 이 기술의 유용성과 향후 성장 가능성에 대한 시장의 신뢰가 높아졌음을 반영합니다.

목차

제1장 분자세포 유전학 시장 : 조사 방법과 범위

제2장 분자세포 유전학 시장 : 주요 요약

• 시장 전망
• 용도 및 기술 현황
• 제품 및 최종 용도 현황
• 경쟁 구도 현황

제3장 분자세포 유전학 시장 : 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
• 산업 분석 툴

제4장 분자세포 유전학 시장 : 용도 비즈니스 분석

• 분자세포 유전학 시장 : 용도 변동 분석
• 유전성 질환
• 종양학
• 맞춤형 의료
• 기타

제5장 분자세포 유전학 시장 : 기술 비즈니스 분석

• 분자세포 유전학 시장 : 기술 변동 분석
• 비교 유전체하이브리다이제이션
• FISH
• 면역조직화학
• 핵형 분석
• 기타

제6장 분자세포 유전학 시장 : 제품 비즈니스 분석

• 분자세포 유전학 시장 : 제품 변동 분석
• 기기
• 소모품
• 소프트웨어 및 서비스

제7장 분자세포 유전학 시장 : 최종 용도 비즈니스 분석

• 분자세포 유전학 시장 : 최종 용도 변동 분석
• 임상실험실
• 병원 및 병리 검사실
• 학술연구기관
• 제약 바이오테크놀러지 기업
• 기타

제7장 분자세포 유전학 시장 : 지역 비즈니스 분석

• 지역 시장 스냅숏
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제8장 분자세포 유전학 시장 : 경쟁 구도

• 기업 분류
• 전략 매핑
• 기업의 시장 점유율 분석, 2024년
• 기업 개요

LSH

영문 목차

영문목차

Molecular Cytogenetics Market Summary

The global molecular cytogenetics market size was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033, growing at a CAGR of 11.7% from 2025 to 2033. The market expansion is supported by the increasing use of molecular cytogenetic techniques in clinical diagnostics and research, particularly in oncology, genetic disorders, and prenatal testing.

These tools offer high-resolution analysis of chromosomal abnormalities, making them essential in modern laboratory and clinical workflows. The growing application of fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and array-based methods contributes to the rising adoption of molecular cytogenetics. Expanding use in personalized medicine and technological improvements in automation and imaging continue to strengthen market demand across hospitals, academic institutions, and research centers.

With the growing volume of genomic data, integrating multi-omics approaches and advancements in bioinformatics tools significantly enhances the molecular cytogenetics field. These enhancements facilitate better management, analysis, and interpretation of large genomic datasets, making it easier to discover meaningful links between chromosomal alterations and diseases. As a result, demand for molecular cytogenetics is expected to grow, with laboratories increasingly relying on these tools for both research and diagnostic applications.

In December 2023, Lupin Diagnostics unveiled a new state-of-the-art Regional Reference Laboratory in Chennai, Tamil Nadu. This laboratory offers a wide range of services, including molecular diagnostics and especially cytogenetics, alongside flow cytometry, cytology, and more. This expansion enhances regional access to high-quality molecular cytogenetic testing and supports better diagnostic capabilities in southern India. Such investments by major diagnostic providers validate cytogenetics' significance in routine clinical practice and reflect growing market confidence in the technology's utility and future growth potential.

Global Molecular Cytogenetics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular cytogenetics market based on application, technology, product, end use, and region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Genetic Disorders
• Oncology
• Personalized Medicine
• Other Applications
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Comparative Genomic Hybridization
  • aCGH
  • sCGH
• FISH
• Immunohistochemistry
• Karyotyping
  • Spectral
  • Virtual
• Others
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Software & Services
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical & Research Laboratories
• Hospitals & Path Labs
• Academic Research Institutes
• Pharmaceutical & Biotech Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1 Molecular Cytogenetics Market: Research Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Technology Segment
    • 1.1.1.3 Product Segment
    • 1.1.1.4 End Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Molecular Cytogenetics Market: Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Technology Snapshot
• 2.3 Product And End Use Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Molecular Cytogenetics Market: Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Related/Ancillary Market Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Drivers Analysis
    • 3.2.1.1 Rapid Technological Advancements
    • 3.2.1.2 Increasing Prevalence Of Genetic Disorders
    • 3.2.1.3 Growing Application In Oncology
    • 3.2.1.4 Increasing Demand For Personalized Medicine
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 High Costs Of Testing
    • 3.2.2.2 Lack Of Reimbursement Policies
• 3.3 Industry Analysis Tools
  • 3.3.1 Porter's Analysis
  • 3.3.2 Pestel Analysis

Chapter 4 Molecular Cytogenetics Market: Application Business Analysis

• 4.1 Molecular Cytogenetics Market: Application Movement Analysis
• 4.2 Genetic Disorders
  • 4.2.1 Genetic Disorders Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 4.3 Oncology
  • 4.3.1 Oncology Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 4.4 Personalized Medicine
  • 4.4.1 Personalized Medicine Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 4.5 Other Application
  • 4.5.1 Other Application Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 5 Molecular Cytogenetics Market: Technology Business Analysis

• 5.1 Molecular Cytogenetics Market: Technology Movement Analysis
• 5.2 Comparative Genomic Hybridisation
  • 5.2.1 Comparative Genomic Hybridisation Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.2.2 Acgh
    • 5.2.2.1 Acgh Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.2.3 Scgh
    • 5.2.3.1 Scgh Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 5.3 Fish
  • 5.3.1 Fish Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 5.4 Immunohistochemistry
  • 5.4.1 Immunohistochemistry Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 5.5 Karyotyping
  • 5.5.1 Karyotyping Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.5.2 Spectral
    • 5.5.2.1 Spectral Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 5.5.3 Virtual
    • 5.5.3.1 Virtual Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 5.6 Others
  • 5.6.1 Others Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 6 Molecular Cytogenetics Market: Product Business Analysis

• 6.1 Molecular Cytogenetics Market: Product Movement Analysis
• 6.2 Instruments
  • 6.2.1 Instruments Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 6.3 Consumables
  • 6.3.1 Consumables Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 6.4 Software & Services
  • 6.4.1 Software & Services Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7 Molecular Cytogenetics Market: End Use Business Analysis

• 7.1 Molecular Cytogenetics Market: End Use Movement Analysis
• 7.2 Clinical & Research Laboratories
  • 7.2.1 Clinical & Research Laboratories Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 7.3 Hospitals & Path Labs
  • 7.3.1 Hospitals & Path Labs Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 7.4 Academic Research Institutes
  • 7.4.1 Academic Research Institutes Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 7.5 Pharmaceutical & Biotech Companies
  • 7.5.1 Pharmaceutical & Biotech Companies Market Estimates And Forecast, 2021 - 2033 (USD Million)
• 7.6 Others
  • 7.6.1 Others Market Estimates And Forecast, 2021 - 2033 (USD Million)

Chapter 7 Molecular Cytogenetics Market: Regional Business Analysis

• 7.1 Regional Market Snapshot
• 7.2 North America
  • 7.2.1 North America Molecular Cytogenetics Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Regulatory Framework
    • 7.2.2.4 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Regulatory Framework
    • 7.2.3.4 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
  • 7.3.2 UK
    • 7.3.2.1 UK Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Regulatory Framework
    • 7.3.2.4 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Regulatory Framework
    • 7.3.3.4 Reimbursement Scenario
  • 7.3.4 Spain
    • 7.3.4.1 Spain Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Regulatory Framework
    • 7.3.4.4 Reimbursement Scenario
  • 7.3.5 France
    • 7.3.5.1 France Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Regulatory Framework
    • 7.3.5.4 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Italy Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Regulatory Framework
    • 7.3.6.4 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Denmark Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Regulatory Framework
    • 7.3.7.4 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Sweden Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Regulatory Framework
    • 7.3.8.4 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Regulatory Framework
    • 7.3.9.4 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia-Pacific Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Japan Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Regulatory Framework
    • 7.4.2.4 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Regulatory Framework
    • 7.4.3.4 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 India Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Regulatory Framework
    • 7.4.4.4. Reimbursement Scenario
  • 7.4.5 South Korea
    • 7.4.5.1 South Korea Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Regulatory Framework
    • 7.4.5.4 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Thailand Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Regulatory Framework
    • 7.4.6.4 Reimbursement Scenario
  • 7.4.7 Australia
    • 7.4.7.1 Australia Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Regulatory Framework
    • 7.4.7.4 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Brazil Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.3 Mexico
    • 7.5.3.1 Mexico Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.4 Argentina
    • 7.5.4.1 Argentina Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.5.4.2 Key Country Dynamics
    • 7.5.4.3 Regulatory Framework
    • 7.5.4.4 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 MEA Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Regulatory Framework
    • 7.6.3.4 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Molecular Cytogenetics Market, 2021 - 2033 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Regulatory Framework
    • 7.6.5.4 Reimbursement Scenario

Chapter 8 Molecular Cytogenetics Market: Competitive Landscape

• 8.1 Company Categorization
• 8.2 Strategy Mapping
  • 8.2.1 New Product Launch
  • 8.2.2 Partnerships
  • 8.2.3 Acquisition
  • 8.2.4 Collaboration
  • 8.2.5 Funding
• 8.3 Company Market Share Analysis, 2024
• 8.4 Company Profiles
  • 8.4.1 Bioview
    • 8.4.1.1 Company Overview
    • 8.4.1.2 Financial Performance
    • 8.4.1.3 Product Benchmarking
    • 8.4.1.4 Strategic Initiatives
  • 8.4.2 Danaher
    • 8.4.2.1 Company Overview
      • 8.4.2.1.1 Leica Biosystems Nussloch Gmbh
    • 8.4.2.2 Financial Performance
    • 8.4.2.3 Product Benchmarking
    • 8.4.2.4 Strategic Initiatives
  • 8.4.3 Metasystems
    • 8.4.3.1 Company Overview
    • 8.4.3.2 Financial Performance
    • 8.4.3.3 Product Benchmarking
    • 8.4.3.4 Strategic Initiatives
  • 8.4.4 Agilent Technologies, Inc.
    • 8.4.4.1 Company Overview
    • 8.4.4.2 Financial Performance
    • 8.4.4.3 Product Benchmarking
    • 8.4.4.4 Strategic Initiatives
  • 8.4.5 Abbott
    • 8.4.5.1 Company Overview
    • 8.4.5.2 Financial Performance
    • 8.4.5.3 Product Benchmarking
    • 8.4.5.4 Strategic Initiatives
  • 8.4.6 Bio-Rad Laboratories, Inc.
    • 8.4.6.1 Company Overview
    • 8.4.6.2 Financial Performance
    • 8.4.6.3 Product Benchmarking
    • 8.4.6.4 Strategic Initiatives
  • 8.4.7 Illumina, Inc.
    • 8.4.7.1 Company Overview
    • 8.4.7.2 Financial Performance
    • 8.4.7.3 Product Benchmarking
    • 8.4.7.4 Strategic Initiatives
  • 8.4.8 Oxford Gene Technology Ip Limited
    • 8.4.8.1 Company Overview
    • 8.4.8.2 Financial Performance
    • 8.4.8.3 Product Benchmarking
    • 8.4.8.4 Strategic Initiatives
  • 8.4.9 F. Hoffmann-La Roche Ltd
    • 8.4.9.1 Company Overview
      • 8.4.9.1.1 Genentech, Inc.
    • 8.4.9.2 Financial Performance
    • 8.4.9.4 Product Benchmarking
    • 8.4.9.5 Strategic Initiatives
  • 8.4.10 Perkinelmer Inc.
    • 8.4.10.1 Company Overview
    • 8.4.10.2 Financial Performance
    • 8.4.10.3 Product Benchmarking
    • 8.4.10.4 Strategic Initiatives

관련자료